Patent · US Active

Substituted aminopyridine compounds as EGFR inhibitors

US11981658B2 · kind B2 · utility

0Cited by
8References
39Claims
0Family size

Assignees

Inventors

Key dates

Filing dateAug 26, 2022
Grant dateMay 14, 2024
Priority date
Expiry dateAug 26, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D493/08
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.